VXRT - Should Investors Bail on Vaxart Stock?
Vaxart (NASDAQ: VXRT) started out 2021 with its stock skyrocketing. However, most of those early gains evaporated after the biotech announced preliminary results from an early-stage clinical study evaluating the company's experimental tablet COVID-19 vaccine. In this Motley Fool Live video, recorded on Feb. 3 , Fool.com contributors Keith Speights and Brian Orelli discuss whether or not investors should now bail on Vaxart stock.
This article represents the opinion of the writer(s), who may disagree with the "official" recommendation position of a Motley Fool premium advisory service. We're motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
For further details see:
Should Investors Bail on Vaxart Stock?